Product news

Share this article:
Stiefel Laboratories announced that the FDA has approved its new drug application for Extina (ketoconazole) foam, 2% for the treatment of seborrheic dermatitis. The approval, which the company received June 12, clears the way for the product to be sold and marketed in the US.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.